Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Biomatrix

This article was originally published in The Gray Sheet

Executive Summary

Biomatrix: Patient enrollment is under way for multi-center U.S. clinicals of Hylagel Uro following FDA approval of an investigational device exemption. Designed to treat urinary incontinence, the viscoelastic gel device is "injected intramuscularly to augment the soft connective tissue between the sphincter and the muscles of the urethra". Biomatrix anticipates its hylan B-based product will compete directly with Collagen's Contigen, a collagen-based urinary incontinence treatment approved in 1993 ("The Gray Sheet" Oct. 4, 1993, p. 1). Biomatrix expects to meet with FDA soon to discuss resubmission of its premarket approval application for its Hylaform viscoelastic gel for use in removing depressed scars and facial wrinkles, which was recently withdrawn. "The Gray Sheet" (Jan. 5, In Brief) incorrectly reported that the company would discuss with FDA the need for additional skin test data on allergic reactions and labeling changes. Biomatrix says there have been no reports of allergic reactions to Hylaform...

You may also be interested in...



Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.

Cosmetic And Personal Care Trademark Review 24 November, 2020

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

CBD Health Benefits More Attractive To Women? FDA Prioritizes Research Into Utero Effects

Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA  neuroscientist Andrew Shen.

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel